Everything we've seen

1. ·Sep 11, 6:02 PMstreamnews

   Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount

   Regeneron (REGN) fits decent value investing: compelling valuation with strong profitability, health, and growth. A balanced opportunity.

2. ·Sep 11, 6:02 PMstreamnews

   Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

   Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsRyan Crowe - Senior...

3. ·Sep 11, 6:02 PMstreamnews

   FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

   NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

4. ·Sep 11, 6:02 PMstreamnews

   Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

   American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

5. ·Sep 11, 6:02 PMstreamnews

   HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

   HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.

6. ·Sep 11, 5:47 PMstreamnews

   Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount

   Regeneron (REGN) fits decent value investing: compelling valuation with strong profitability, health, and growth. A balanced opportunity.

7. ·Sep 11, 5:47 PMstreamnews

   Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

   Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsRyan Crowe - Senior...

8. ·Sep 11, 5:47 PMstreamnews

   FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

   NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

9. ·Sep 11, 5:47 PMstreamnews

   Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

   American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

10. ·Sep 11, 5:47 PMstreamnews

    HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

    HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.

11. ·Sep 11, 5:31 PMstreamnews

    Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount

    Regeneron (REGN) fits decent value investing: compelling valuation with strong profitability, health, and growth. A balanced opportunity.

12. ·Sep 11, 5:31 PMstreamnews

    Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsRyan Crowe - Senior...

13. ·Sep 11, 5:31 PMstreamnews

    FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

    NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

14. ·Sep 11, 5:31 PMstreamnews

    Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

    American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

15. ·Sep 11, 5:31 PMstreamnews

    HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

    HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.

16. ·Sep 11, 5:16 PMstreamnews

    Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount

    Regeneron (REGN) fits decent value investing: compelling valuation with strong profitability, health, and growth. A balanced opportunity.

17. ·Sep 11, 5:16 PMstreamnews

    Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsRyan Crowe - Senior...

18. ·Sep 11, 5:16 PMstreamnews

    FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

    NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

19. ·Sep 11, 5:16 PMstreamnews

    Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

    American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

20. ·Sep 11, 5:16 PMstreamnews

    HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

    HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.

21. ·Sep 11, 5:01 PMstreamnews

    Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount

    Regeneron (REGN) fits decent value investing: compelling valuation with strong profitability, health, and growth. A balanced opportunity.

22. ·Sep 11, 5:01 PMstreamnews

    Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsRyan Crowe - Senior...

23. ·Sep 11, 5:01 PMstreamnews

    FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

    NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

24. ·Sep 11, 5:01 PMstreamnews

    Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

    American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

25. ·Sep 11, 5:01 PMstreamnews

    HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

    HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.

26. ·Sep 11, 4:45 PMstreamnews

    Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount

    Regeneron (REGN) fits decent value investing: compelling valuation with strong profitability, health, and growth. A balanced opportunity.

27. ·Sep 11, 4:45 PMstreamnews

    Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsRyan Crowe - Senior...

28. ·Sep 11, 4:45 PMstreamnews

    FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

    NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

29. ·Sep 11, 4:45 PMstreamnews

    Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

    American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

30. ·Sep 11, 4:45 PMstreamnews

    HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

    HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.

31. ·Sep 11, 4:32 PMstreamnews

    Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount

    Regeneron (REGN) fits decent value investing: compelling valuation with strong profitability, health, and growth. A balanced opportunity.

32. ·Sep 11, 4:32 PMstreamnews

    Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsRyan Crowe - Senior...

33. ·Sep 11, 4:32 PMstreamnews

    FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

    NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

34. ·Sep 11, 4:32 PMstreamnews

    Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

    American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

35. ·Sep 11, 4:32 PMstreamnews

    HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

    HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.

36. ·Sep 11, 4:15 PMstreamnews

    Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount

    Regeneron (REGN) fits decent value investing: compelling valuation with strong profitability, health, and growth. A balanced opportunity.

37. ·Sep 11, 4:15 PMstreamnews

    Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsRyan Crowe - Senior...

38. ·Sep 11, 4:15 PMstreamnews

    FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

    NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

39. ·Sep 11, 4:15 PMstreamnews

    Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

    American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

40. ·Sep 11, 4:15 PMstreamnews

    HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

    HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.

41. ·Sep 11, 4:00 PMstreamnews

    Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

    American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

42. ·Sep 11, 4:00 PMstreamnews

    HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

    HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.

43. ?Sep 11, 9:35 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down -1.78% today with no attributable news catalyst. This is a meaningful but not outsized move — below the 2% threshold where momentum becomes more self-sustaining. With 370 minutes remaining (essentially a full remaining session), there is ample time for either continuation or mean reversion. The macro context shows elevated 5-year forward inflation expectations (T5YIFR at 1.8σ above trend), which is broadly rate-sensitive but has limited direct read-through to a large-cap biotech like REGN, which is not particularly rate-sensitive in its earnings drivers. No news headlines are present, so the move likely reflects either sector rotation, broader risk-off flow, or idiosyncratic institutional selling. Without a clear catalyst or evidence of heavy volume conviction, and given REGN's historically mean-reverting intraday behavior as a high-priced biotech name, this sits at a borderline read. The absence of news does not disqualify continuation, and the system's bounded risk profile supports taking the directional lean. Assigning minimum trigger probability — down continuation is the base case given observed momentum, but confidence is low.

44. !Sep 11, 9:35 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down -1.78% today with no attributable news catalyst. This is a meaningful but not outsized move — below the 2% threshold where momentum becomes more self-sustaining. With 370 minutes remaining (essentially a full remaining session), there is ample time for either continuation or mean reversion. The macro context shows elevated 5-year forward inflation expectations (T5YIFR at 1.8σ above trend), which is broadly rate-sensitive but has limited direct read-through to a large-cap biotech like REGN, which is not particularly rate-sensitive in its earnings drivers. No news headlines are present, so the move likely reflects either sector rotation, broader risk-off flow, or idiosyncratic institutional selling. Without a clear catalyst or evidence of heavy volume conviction, and given REGN's historically mean-reverting intraday behavior as a high-priced biotech name, this sits at a borderline read. The absence of news does not disqualify continuation, and the system's bounded risk profile supports taking the directional lean. Assigning minimum trigger probability — down continuation is the base case given observed momentum, but confidence is low.

45. ▣Sep 10, 8:00 PMjournalstop

    Agent 2 — Adaptive closed long 11 @ $781.49 (-$775.94)

    Long trailing stop: close $781.49 ≤ trailing floor $792.39 (peak × 0.93)

46. ?Sep 10, 12:45 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down 1.65% today, which is a moderate but not outsized move. There are no recent headlines to attribute the decline to, suggesting either broad sector rotation or quiet institutional selling. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend — this is modestly bearish for rate-sensitive and growth/biotech names like REGN, as elevated inflation expectations can pressure discount rates applied to future earnings. However, the effect is indirect and not a strong catalyst. With 180 minutes remaining there is ample time for continuation, but the move itself (-1.65%) is below the threshold where strong directional conviction typically builds. No reversal signals are evident, but equally no clear acceleration or volume surge is noted. The asymmetry of the system (tight -1.5% stop, +3% target, bounded risk) supports taking the modest continuation trade. Probability is set at the floor of the actionable range — there is mild macro support for further downside in biotech/growth but no strong conviction signal.

47. !Sep 10, 12:45 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down 1.65% today, which is a moderate but not outsized move. There are no recent headlines to attribute the decline to, suggesting either broad sector rotation or quiet institutional selling. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend — this is modestly bearish for rate-sensitive and growth/biotech names like REGN, as elevated inflation expectations can pressure discount rates applied to future earnings. However, the effect is indirect and not a strong catalyst. With 180 minutes remaining there is ample time for continuation, but the move itself (-1.65%) is below the threshold where strong directional conviction typically builds. No reversal signals are evident, but equally no clear acceleration or volume surge is noted. The asymmetry of the system (tight -1.5% stop, +3% target, bounded risk) supports taking the modest continuation trade. Probability is set at the floor of the actionable range — there is mild macro support for further downside in biotech/growth but no strong conviction signal.

48. ❖Sep 10, 5:38 AMnewsvia finnhub

    HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

    HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.

49. ❖Sep 9, 10:51 AMnewsvia finnhub

    Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)

    American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

50. ❖Sep 9, 10:05 AMnewsvia finnhub

    FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

    NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

51. ❖Sep 9, 8:27 AMnewsvia finnhub

    Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsRyan Crowe - Senior...

52. ❖Sep 9, 7:52 AMnewsvia finnhub

    Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount

    Regeneron (REGN) fits decent value investing: compelling valuation with strong profitability, health, and growth. A balanced opportunity.

53. ❖Sep 8, 11:41 AMnewsvia finnhub

    Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock

    Harbor Funds, an investment management company, released its Q2 2026 investor letter for “Harbor Mid Cap Value Fund”. The letter can be downloaded here. Global equities experienced a sharp rally in Q2 2026, with the S&P 500 returning 15.2%, its strongest quarter since 2020, driven by a shift from software to hardware in the Artificial Intelligence […]

54. ❖Sep 8, 10:05 AMnewsvia finnhub

    Big Short Billionaire Goes Long: Michael Burry Avoids AI, Bets on Beaten own Stocks Instead

    While Wall Street piles into AI darlings, Michael Burry is quietly loading up on call options in three stocks the market left for dead, and his biggest bets carry a very specific thesis about where the crowd got it wrong.

55. ❖Sep 8, 9:51 AMnewsvia finnhub

    3 Reasons to Avoid REGN and 1 Stock to Buy Instead

    Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that period. This may have investors wondering how to approach the situation.

56. ?Sep 8, 9:45 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down 1.52% today, which is a moderate but not extreme intraday move. No specific catalyst headline is attributable to today's move — the only recent news is a positive sector piece about IBB outperforming, which is mildly contradictory to the down move (biotech sector strength could provide support/pullback to the decline). Macro context shows 5Y forward inflation expectations elevated at 1.7σ above trend, which broadly pressures rate-sensitive and growth-oriented sectors like biotech, providing some tailwind to the downside thesis. However, with 360 minutes remaining (essentially a full trading day still ahead), the move has had time to develop but also plenty of time to reverse — the extended time window cuts both ways. The IBB sector outperformance narrative is a mild headwind against continuation lower. The move at -1.52% is meaningful but not large enough to signal heavy institutional conviction on its own. Balancing the modest macro headwind (elevated inflation expectations hurting growth stocks) against the positive sector backdrop and absence of a specific bearish catalyst, this is a borderline read. Assigning 0.5 — the minimum threshold to take the trade given the system's bounded risk parameters and the slight macro support for further weakness in rate-sensitive growth names.

57. !Sep 8, 9:45 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down 1.52% today, which is a moderate but not extreme intraday move. No specific catalyst headline is attributable to today's move — the only recent news is a positive sector piece about IBB outperforming, which is mildly contradictory to the down move (biotech sector strength could provide support/pullback to the decline). Macro context shows 5Y forward inflation expectations elevated at 1.7σ above trend, which broadly pressures rate-sensitive and growth-oriented sectors like biotech, providing some tailwind to the downside thesis. However, with 360 minutes remaining (essentially a full trading day still ahead), the move has had time to develop but also plenty of time to reverse — the extended time window cuts both ways. The IBB sector outperformance narrative is a mild headwind against continuation lower. The move at -1.52% is meaningful but not large enough to signal heavy institutional conviction on its own. Balancing the modest macro headwind (elevated inflation expectations hurting growth stocks) against the positive sector backdrop and absence of a specific bearish catalyst, this is a borderline read. Assigning 0.5 — the minimum threshold to take the trade given the system's bounded risk parameters and the slight macro support for further weakness in rate-sensitive growth names.

58. ❖Sep 7, 12:22 PMnewsvia finnhub

    IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?

    Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?

59. ?Sep 4, 6:02 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $827.69 > MA150 $724.39 (+14.3%), MA rising, 3.7% off 52w high, vol 0.48× avg

60. ❖Sep 4, 2:50 PMnewsvia finnhub

    Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

    They could both outperform the market over the medium term, but one appears to have a clear edge.

61. ❖Sep 4, 11:30 AMnewsvia finnhub

    Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?

    Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

62. ❖Sep 4, 8:00 AMnewsvia finnhub

    Trailing rivals, AbbVie scores win with dual-acting myeloma drug

    The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

63. ❖Sep 4, 12:38 AMnewsvia finnhub

    Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?

    Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...

64. ?Sep 3, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $843.47 > MA150 $723.81 (+16.5%), MA rising, 1.8% off 52w high, vol 0.69× avg

65. ?Sep 2, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $852.03 > MA150 $723.18 (+17.8%), MA rising, 0.3% off 52w high, vol 1.07× avg

66. ✓Sep 2, 6:03 PMdecisionacted

    Agent 2 — Adaptive — entry

    Stage 2: close $852.03 > MA150 $723.18 (+17.8%), MA rising, 0.3% off 52w high, vol 1.07× avg

67. ?Sep 2, 3:16 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is up 3.29% with only 30 minutes until the forced close cutoff. The move is meaningful and represents real conviction, but the critical constraint here is time — with just 30 minutes remaining, there is very limited runway for the +3% profit target to be reached from current levels, and the risk/reward of chasing a 3.29% move in the final 30 minutes skews toward mean reversion or consolidation rather than further extension. No news catalyst is present to explain the move, which cuts both ways — it could be institutional flow with more to come, or it could be a move that has already run its course. The macro context (5Y5Y inflation forward 1.7σ above trend) is modestly unfavorable for rate-sensitive and growth-oriented large-cap biotech names like REGN, as elevated inflation expectations can pressure multiples. With no catalyst to anchor the move and time too short to realistically hit the profit target without overshoot risk, the setup does not clear the threshold for a trade.

68. !Sep 2, 3:16 PMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    REGN is up 3.29% with only 30 minutes until the forced close cutoff. The move is meaningful and represents real conviction, but the critical constraint here is time — with just 30 minutes remaining, there is very limited runway for the +3% profit target to be reached from current levels, and the risk/reward of chasing a 3.29% move in the final 30 minutes skews toward mean reversion or consolidation rather than further extension. No news catalyst is present to explain the move, which cuts both ways — it could be institutional flow with more to come, or it could be a move that has already run its course. The macro context (5Y5Y inflation forward 1.7σ above trend) is modestly unfavorable for rate-sensitive and growth-oriented large-cap biotech names like REGN, as elevated inflation expectations can pressure multiples. With no catalyst to anchor the move and time too short to realistically hit the profit target without overshoot risk, the setup does not clear the threshold for a trade.

69. ❖Sep 2, 8:45 AMnewsvia finnhub

    Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years

    Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 17.79%. Currently, Regeneron Pharmaceuticals has a market

70. ❖Sep 2, 8:17 AMnewsvia finnhub

    2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

    Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Leading Drugs, Key Geographical Regions and Leading Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global complement inhibitors market is projected to increase fr

71. ❖Sep 2, 7:30 AMnewsvia finnhub

    Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?

    Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.

72. ▢Sep 1, 8:00 PMjournal

    Agent 2 — Adaptive opened long 11 @ $852.03

73. ?Sep 1, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $824.42 > MA150 $722.52 (+14.1%), MA rising, 2.7% off 52w high, vol 1.60× avg

74. ?Sep 1, 6:02 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $824.42 > MA150 $722.52 (+14.1%), MA rising, 2.7% off 52w high, vol 1.60× avg

75. ?Sep 1, 11:00 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is up 1.86% today, which is a moderate but meaningful intraday move suggesting real buying flow. However, several factors temper enthusiasm: (1) No news catalyst is identifiable, making it harder to assess whether institutional conviction is behind the move or if it was driven by technical/flow factors that may already be exhausted. (2) The macro backdrop shows elevated 2Y yields (4.34, +2σ above trend), which is modestly unfavorable for growth/biotech names like REGN as higher rates compress long-duration valuations. (3) At 285 minutes remaining (early-to-mid session), there is ample time for continuation, which is a positive, but also ample time for mean reversion if the move was front-loaded. (4) The move is below the 2-5% threshold that would indicate unusually strong conviction. On balance, with no counter-evidence strong enough to warrant a fade call, the default lean per the system rules is mild continuation. Probability just above the 0.5 threshold reflects an ordinary momentum setup with no strong tailwind but also no clear reversal signal.

76. !Sep 1, 11:00 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is up 1.86% today, which is a moderate but meaningful intraday move suggesting real buying flow. However, several factors temper enthusiasm: (1) No news catalyst is identifiable, making it harder to assess whether institutional conviction is behind the move or if it was driven by technical/flow factors that may already be exhausted. (2) The macro backdrop shows elevated 2Y yields (4.34, +2σ above trend), which is modestly unfavorable for growth/biotech names like REGN as higher rates compress long-duration valuations. (3) At 285 minutes remaining (early-to-mid session), there is ample time for continuation, which is a positive, but also ample time for mean reversion if the move was front-loaded. (4) The move is below the 2-5% threshold that would indicate unusually strong conviction. On balance, with no counter-evidence strong enough to warrant a fade call, the default lean per the system rules is mild continuation. Probability just above the 0.5 threshold reflects an ordinary momentum setup with no strong tailwind but also no clear reversal signal.

77. ?Aug 31, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $799.41 > MA150 $722.16 (+10.7%), MA rising, 5.6% off 52w high, vol 1.74× avg

78. ❖Aug 31, 10:57 AMnewsvia finnhub

    Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know

79. ❖Aug 31, 6:50 AMnewsvia finnhub

    Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs

    Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.

80. ❖Aug 31, 6:03 AMnewsvia finnhub

    Non-Melanoma Skin Cancer Market: Focus on Disease Indication, Treatment Type, Country and Region, 2025-2035

    The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtay

81. ▣Aug 30, 8:00 PMjournaltime_stop

    Agent 5 — Dip Buyer (Evolving) closed long 2 @ $794.19 (+$316.32)

    Time stop: held 91 ≥ 90 days

82. ?Aug 28, 1:05 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down 2.18% with 160 minutes remaining — a meaningful intraday move with ample time for continuation. There are no headlines to explain the move, which is consistent with institutional selling or sector rotation rather than a news-driven spike that might exhaust quickly. The macro context (elevated mortgage rates) is not directly relevant to REGN's biotech/pharma business, so there is no macro tailwind to fade the move. With no reversal signals evident and moderate time remaining, the default lean is mild continuation of the established intraday trend. However, the absence of any catalyst and the fact that this is approaching the lower end of a 2-5% move that could attract dip buyers limits conviction. Probability set at 0.52 — modest continuation bias without strong confirmatory evidence.

83. !Aug 28, 1:05 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down 2.18% with 160 minutes remaining — a meaningful intraday move with ample time for continuation. There are no headlines to explain the move, which is consistent with institutional selling or sector rotation rather than a news-driven spike that might exhaust quickly. The macro context (elevated mortgage rates) is not directly relevant to REGN's biotech/pharma business, so there is no macro tailwind to fade the move. With no reversal signals evident and moderate time remaining, the default lean is mild continuation of the established intraday trend. However, the absence of any catalyst and the fact that this is approaching the lower end of a 2-5% move that could attract dip buyers limits conviction. Probability set at 0.52 — modest continuation bias without strong confirmatory evidence.

84. ?Aug 28, 11:05 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down 1.71% today, a moderate but not extreme move. There are no recent headlines to explain the move, suggesting it may be flow/technical driven rather than a catalyst-driven selloff. The macro context (elevated mortgage rates) is not directly relevant to REGN as a biotech/pharma name, providing no sector-level tailwind or headwind. With 280 minutes remaining (essentially the full remaining session), there is ample time for continuation, but also for mean reversion. The move is below the 2% threshold where momentum tends to be more self-sustaining. No reversal pattern is evident from the data provided, and absence of news does not disqualify continuation. On balance, this is a borderline read — mild downward momentum with no clear catalyst and no macro pressure specific to the sector. Assigning 0.5 to reflect genuine uncertainty with a slight lean toward continuation given the system's asymmetric risk structure.

85. !Aug 28, 11:05 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down 1.71% today, a moderate but not extreme move. There are no recent headlines to explain the move, suggesting it may be flow/technical driven rather than a catalyst-driven selloff. The macro context (elevated mortgage rates) is not directly relevant to REGN as a biotech/pharma name, providing no sector-level tailwind or headwind. With 280 minutes remaining (essentially the full remaining session), there is ample time for continuation, but also for mean reversion. The move is below the 2% threshold where momentum tends to be more self-sustaining. No reversal pattern is evident from the data provided, and absence of news does not disqualify continuation. On balance, this is a borderline read — mild downward momentum with no clear catalyst and no macro pressure specific to the sector. Assigning 0.5 to reflect genuine uncertainty with a slight lean toward continuation given the system's asymmetric risk structure.

86. ❖Aug 28, 8:43 AMnewsvia finnhub

    World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency

    https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report

87. ❖Aug 27, 8:29 AMnewsvia finnhub

    Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment

    Corvus Pharmaceuticals has delivered strong soquelitinib data in atopic dermatitis, driving a significant market rally and a robust cash raise. Learn more about CRVS stock here.

88. ❖Aug 27, 4:08 AMnewsvia finnhub

    GSK: Still One Of My Top Healthcare Picks

    GSK stock outlook: FDA bepirovirsen Oct 26 decision, Phase 3 OCEAN results, and reaffirmed 2026 guidance. Read here for a detailed investment analysis.

89. ▣Aug 26, 8:00 PMjournalmanual

    Agent 8 — Dip Buyer (Peer-Aware) closed long 1 @ $827.78 (+$193.24)

    Time stop: held 90 ≥ 90 days

90. ?Aug 26, 6:02 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $814.80 > MA150 $721.30 (+13.0%), MA rising, 3.8% off 52w high, vol 0.37× avg

91. ?Aug 26, 3:15 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down 1.71% with only 30 minutes remaining until forced close. The move is below the 2-5% threshold that would signal strong conviction flow, making it a moderate rather than compelling momentum signal. With only 30 minutes left, there is very limited time for continuation to develop meaningfully before the 3:45 PM ET cutoff. No catalytic headlines are present to explain or sustain the move, and while absence of news isn't disqualifying, it provides no incremental support. The macro context (T5YIFR elevated 1.6σ above trend) suggests rate-sensitive sectors face headwinds, but REGN as a biotech/large-cap pharma is not strongly rate-sensitive in the short-term intraday sense. Late-session dynamics often see mean reversion in moderate-sized moves absent a clear catalyst, as profit-taking on short positions and EOD rebalancing can lift prices. The combination of limited time remaining, sub-2% move size, no news driver, and typical late-day fade dynamics leads to a below-0.5 probability for continuation downward.

92. !Aug 26, 3:15 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down 1.71% with only 30 minutes remaining until forced close. The move is below the 2-5% threshold that would signal strong conviction flow, making it a moderate rather than compelling momentum signal. With only 30 minutes left, there is very limited time for continuation to develop meaningfully before the 3:45 PM ET cutoff. No catalytic headlines are present to explain or sustain the move, and while absence of news isn't disqualifying, it provides no incremental support. The macro context (T5YIFR elevated 1.6σ above trend) suggests rate-sensitive sectors face headwinds, but REGN as a biotech/large-cap pharma is not strongly rate-sensitive in the short-term intraday sense. Late-session dynamics often see mean reversion in moderate-sized moves absent a clear catalyst, as profit-taking on short positions and EOD rebalancing can lift prices. The combination of limited time remaining, sub-2% move size, no news driver, and typical late-day fade dynamics leads to a below-0.5 probability for continuation downward.

93. ?Aug 26, 11:00 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down 1.69% with 285 minutes remaining — a meaningful but not outsized move. No news catalyst is present to explain the move, which cuts both ways: no headline to chase, but also no catalyst to sustain forced selling. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is modestly negative for rate-sensitive and high-multiple biotech names like REGN (P/E ~20x, but large-cap biotech often trades with growth-stock sensitivity). However, this macro signal is not dramatically novel and is unlikely to drive fresh aggressive selling specifically into REGN today. With 285 minutes remaining there is ample time for continuation, but the sub-2% move size suggests this is more noise than a conviction flush — absent a clear catalyst or unusually heavy volume signature, the probability of a sustained directional grind lower into the close is roughly coin-flip. The elevated inflation expectations provide a mild headwind but not enough to push this clearly above 0.5 for continuation. Slight lean toward not triggering given the borderline magnitude and lack of confirming catalyst; calling this just below the 0.5 threshold.

94. !Aug 26, 11:00 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down 1.69% with 285 minutes remaining — a meaningful but not outsized move. No news catalyst is present to explain the move, which cuts both ways: no headline to chase, but also no catalyst to sustain forced selling. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is modestly negative for rate-sensitive and high-multiple biotech names like REGN (P/E ~20x, but large-cap biotech often trades with growth-stock sensitivity). However, this macro signal is not dramatically novel and is unlikely to drive fresh aggressive selling specifically into REGN today. With 285 minutes remaining there is ample time for continuation, but the sub-2% move size suggests this is more noise than a conviction flush — absent a clear catalyst or unusually heavy volume signature, the probability of a sustained directional grind lower into the close is roughly coin-flip. The elevated inflation expectations provide a mild headwind but not enough to push this clearly above 0.5 for continuation. Slight lean toward not triggering given the borderline magnitude and lack of confirming catalyst; calling this just below the 0.5 threshold.

95. ?Aug 25, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $833.56 > MA150 $720.86 (+15.6%), MA rising, 1.6% off 52w high, vol 0.62× avg

96. ?Aug 25, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $833.56 > MA150 $720.86 (+15.6%), MA rising, 1.6% off 52w high, vol 0.62× avg

97. ❖Aug 25, 5:01 AMnewsvia finnhub

    Regeneron: Why I Still See Upside After The Rally

    Regeneron Pharmaceuticals, Inc. stock outlook: Eylea pressure eases as Dupixent jumps; FDA OKs Pasatru. Read why REGN stock is a buy.

98. ?Aug 24, 6:03 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $828.57 > MA150 $720.20 (+15.0%), MA rising, 2.2% off 52w high, vol 0.49× avg

99. ?Aug 24, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $828.57 > MA150 $720.20 (+15.0%), MA rising, 2.2% off 52w high, vol 0.49× avg

100. ❖Aug 24, 3:45 PMnewsvia finnhub

     $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

     Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 19.2%. Currently, Regeneron Pharmaceuticals has a market

101. ❖Aug 24, 4:52 AMnewsvia finnhub

     Sanofi: Trump's Vaccine Policy Won't Break The Story

     Sanofi stock faces temporary pressure after Trump’s vaccine order, but trades cheap (9.2x P/E) with raised 2026 guidance. Click for this SNY update.

102. ❖Aug 11, 5:30 AMnewsvia finnhub

     American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review

     U.S. equities posted double-digit quarterly gains despite volatility stemming from the Iran conflict. Read more here.

103. ?Aug 10, 6:04 PMdecisionconsidered

     Agent 20 — SIR Price/Volume — skip_cash

     Bullish PV but only $1320 cash; need $2424.

104. ?Aug 10, 3:16 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     REGN is up 3.12% today with no attributable headline, suggesting institutional flow or sector rotation is driving the move. However, with only 30 minutes remaining until the forced close, the time window is critically compressed — even strong momentum setups often exhaust or reverse in the final 30 minutes as intraday traders take profits and MMs flatten books. The macro context (T5YIE 1.6σ below trend) signals a low real-rate / risk-on tilt that is more supportive of growth/biotech in general, but this is a weak tailwind at best. The absence of a catalyst means there is no news-driven narrative to sustain buying pressure into the close. The 3.12% move is meaningful, but at this stage of day it is more likely reflecting morning/midday momentum that has largely played out. With 30 minutes left, the risk-reward of chasing a 3% gainer into the close without a clear catalyst does not clear the 0.5 threshold — the position would need to gain another ~3% to hit target while the stop is only 1.5% away, and late-session fades on catalyst-less large moves are common. Probability set just below trigger.

105. !Aug 10, 3:16 PMsignalseverity 0.03

     Agent 7 — Day Trader — day_trade_skipped

     REGN is up 3.12% today with no attributable headline, suggesting institutional flow or sector rotation is driving the move. However, with only 30 minutes remaining until the forced close, the time window is critically compressed — even strong momentum setups often exhaust or reverse in the final 30 minutes as intraday traders take profits and MMs flatten books. The macro context (T5YIE 1.6σ below trend) signals a low real-rate / risk-on tilt that is more supportive of growth/biotech in general, but this is a weak tailwind at best. The absence of a catalyst means there is no news-driven narrative to sustain buying pressure into the close. The 3.12% move is meaningful, but at this stage of day it is more likely reflecting morning/midday momentum that has largely played out. With 30 minutes left, the risk-reward of chasing a 3% gainer into the close without a clear catalyst does not clear the 0.5 threshold — the position would need to gain another ~3% to hit target while the stop is only 1.5% away, and late-session fades on catalyst-less large moves are common. Probability set just below trigger.

106. ❖Aug 8, 7:11 PMnewsvia finnhub

     Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight

     Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing second quarter and half year 2026 results, and updating on recent share repurchases. See our latest analysis for Regeneron Pharmaceuticals. Alongside the latest dividend and earnings update, Regeneron Pharmaceuticals’ recent share price return of 18.33% over 30 days and 9.72% over 90 days suggests momentum has...

107. ❖Aug 7, 10:46 AMnewsvia finnhub

     NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

     Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

108. ❖Aug 6, 9:03 PMnewsvia finnhub

     CytomX Therapeutics Q2 Earnings Call Highlights

     CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv

109. ❖Aug 6, 4:15 PMnewsvia finnhub

     CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

     Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 - - Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarc

110. ❖Aug 6, 4:15 PMnewsvia finnhub

     CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

     Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 - - Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarc

111. ❖Aug 6, 3:03 PMnewsvia finnhub

     Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ...

     Intellia reports positive Phase III data for LONVOSI, resumes NEXI trials with new HLA safety insights, and maintains cash runway into 2028.

112. ❖Aug 6, 7:35 AMnewsvia finnhub

     LibtayoReceives Health Canada Approval for Adjuvant Treatment Of High-Risk Cutaneous Squamous Cell Carcinoma

     https://www.newswire.ca/news-releases/libtayo-r-cemiplimab-for-injection-receives-health-canada-approval-for-adjuvant-treatment-of-high-risk-cutaneous-squamous-cell-carcinoma-809797655.html

113. ❖Aug 6, 4:00 AMnewsvia finnhub

     Regeneron Founder and CEO Leonard Schleifer on America’s entrepreneurial spirit

     Regeneron Founder and CEO Leonard Schleifer reflects on his company’s legacy in pharmaceutical innovation, and how America’s spirit of entrepreneurship paved the way for Regeneron’s growth.

114. ▣Aug 5, 8:00 PMjournalmanual

     Agent 8 — Dip Buyer (Peer-Aware) closed long 1 @ $767.98 (+$133.44)

     Staged exit (1/2.0): close $768.58 ≥ target $767.21. Selling 1/2 sh, trailing remainder.

115. ❖Aug 5, 12:20 PMnewsvia finnhub

     Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stock

     Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

116. ❖Aug 5, 12:05 PMnewsvia finnhub

     Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan

     Teva Pharmaceutical Industries Limited turnaround: Pivot to Growth, raised 2026 guidance, $3.7B specialty target, and more. Click for this TEVA update.

117. ❖Aug 5, 11:49 AMnewsvia finnhub

     Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

     RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.

118. ❖Aug 5, 11:40 AMnewsvia finnhub

     REGN or INCY: Which Is the Better Value Stock Right Now?

     REGN vs. INCY: Which Stock Is the Better Value Option?

119. ▣Aug 4, 8:00 PMjournaltarget

     Agent 8 — Dip Buyer (Peer-Aware) closed long 1 @ $768.95 (+$134.41)

     Staged exit (1/2.0): close $768.95 ≥ target $767.21. Selling 1/3 sh, trailing remainder.

120. ▣Aug 4, 8:00 PMjournaltarget

     Agent 5 — Dip Buyer (Evolving) closed long 2 @ $768.95 (+$265.84)

     Staged exit (1/2.0): close $768.95 ≥ target $767.21. Selling 2/4 sh, trailing remainder.

121. ❖Aug 4, 11:57 AMnewsvia finnhub

     BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth

     Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.

122. ❖Aug 4, 9:55 AMnewsvia finnhub

     OPKO Health: Mazdutide And MDX-2201 Could Change Everything

     OPKO Health's Q2 results: IP revenue surged on Nicoya deal and FY2026 guidance rose. Click for this OPK stock update.

123. ❖Aug 3, 10:43 AMnewsvia finnhub

     Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740

     Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $700 to $740.

124. ❖Aug 3, 9:35 AMnewsvia finnhub

     6 Health Care Stocks Whale Activity In Today’s Session

     This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

125. ❖Aug 3, 7:05 AMnewsvia finnhub

     Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg

     BENGALURU, India & BRIDGEWATER, N.J., August 03, 2026--Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg, Used to Treat Various Types of Ophthalmology Conditions

126. ❖Aug 3, 6:22 AMnewsvia finnhub

     Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030

     Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1000 to $1030.

127. ❖Jul 31, 10:03 PMnewsvia finnhub

     REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance

     Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion. Its non-GAAP profit of $14.29 per share was 40.1% above analysts’ consensus estimates.

128. ❖Jul 31, 3:29 PMnewsvia finnhub

     Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?

     The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.

129. ❖Jul 31, 1:22 PMnewsvia finnhub

     AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling.

     AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics.

130. ❖Jul 31, 11:39 AMnewsvia finnhub

     RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $737

     RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $696 to $737.

131. ❖Jul 31, 10:21 AMnewsvia finnhub

     AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.

     AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.

132. ❖Jul 31, 9:47 AMnewsvia finnhub

     Company News for July 31, 2026

     Companies in The News Are: MA,BMY,MO,REGN

133. ?Jul 30, 6:03 PMdecisionconsidered

     Agent 20 — SIR Price/Volume — buy

     [not executed — reserve_floor_or_cash] [cluster_break_up] From 2026-07-06 through 2026-07-27, REGN traced a tight 20-day price cluster largely bounded between ~$651 and ~$679 on consistently low, routine volume (ranging from 478K on 2026-07-14 to a high of 1.1M on 2026-07-23, with a trailing 20-day ADV of only 745K). That cluster represents an extended period of price compression and absorbed selling. The path then began a constructive lift — 2026-07-28 closed $695.18 on 900K, 2026-07-29 held that gain at $695.42 on 1.0M (confirming, not just a one-day spike) — before today, 2026-07-30, delivered a decisive +6.18% close at $738.41 on 2.4M shares, a volume z-score of 8.83 versus the 20-day mean. In SIR's 2-D framework, the scatter path broke sharply up-and-right out of the multi-week cluster on volume that was more than 3× the prior session and more than 3× ADV, the hallmark signature of fresh, urgent demand absorbing the float. Risks: A single-session catalyst (e.g., earnings surprise or drug-approval news) could mean today's volume is non-recurring institutional flow rather than the onset of sustained accumulation — if the next 2-3 sessions fail to hold above the cluster ceiling (~$695) on above-average volume, the breakout would be considered a false break and the bullish read is invalidated. Additionally, the macro environment (5-year inflation expectations at a 1.5σ below-trend print of 2.24) favors defensive/inflation-linked sectors over Health Care, which could suppress sector-level sponsorship needed to sustain the move.

134. ?Jul 29, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $695.85 < MA150 $717.78 (-3.1%), MA falling, 15.3% off 52w high, vol 1.17× avg

135. ?Jul 23, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $651.87 < MA150 $719.77 (-9.4%), MA falling, 20.6% off 52w high, vol 1.11× avg

136. ?Jul 23, 10:10 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     REGN is down 1.68% today with no specific catalyst identified in recent headlines. The move is below the 2-5% threshold that would signal strong institutional conviction, sitting in a moderate range. With 335 minutes remaining (roughly 5.5 hours, suggesting this is near market open or early session), there is ample time for the move to either continue or reverse. The macro context shows a flattening yield curve (T10Y2Y at 1.8σ below trend), which tends to favor defensives — biotech/pharma like REGN can benefit from defensive rotation, but this is a mild tailwind at best and doesn't strongly support a reversal. Absence of news means no catalyst to reverse the current drift. REGN as a large-cap biotech is subject to sector-wide selling pressure that can persist intraday without a headline driver. With no reversal pattern evident and time remaining for the move to develop, the base case is modest continuation of the downward drift, though conviction is low given the sub-2% magnitude and lack of news.

137. !Jul 23, 10:10 AMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     REGN is down 1.68% today with no specific catalyst identified in recent headlines. The move is below the 2-5% threshold that would signal strong institutional conviction, sitting in a moderate range. With 335 minutes remaining (roughly 5.5 hours, suggesting this is near market open or early session), there is ample time for the move to either continue or reverse. The macro context shows a flattening yield curve (T10Y2Y at 1.8σ below trend), which tends to favor defensives — biotech/pharma like REGN can benefit from defensive rotation, but this is a mild tailwind at best and doesn't strongly support a reversal. Absence of news means no catalyst to reverse the current drift. REGN as a large-cap biotech is subject to sector-wide selling pressure that can persist intraday without a headline driver. With no reversal pattern evident and time remaining for the move to develop, the base case is modest continuation of the downward drift, though conviction is low given the sub-2% magnitude and lack of news.

138. ?Jul 22, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $651.18 < MA150 $720.44 (-9.6%), MA falling, 20.7% off 52w high, vol 1.50× avg

139. ?Jul 22, 6:00 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $651.18 < MA150 $720.44 (-9.6%), MA falling, 20.7% off 52w high, vol 1.50× avg

140. ?Jul 21, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $675.19 < MA150 $721.04 (-6.4%), MA falling, 17.8% off 52w high, vol 0.56× avg

141. ?Jul 20, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $672.15 < MA150 $721.52 (-6.8%), MA falling, 18.1% off 52w high, vol 0.62× avg

142. ?Jul 17, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $676.69 < MA150 $721.88 (-6.3%), MA falling, 17.6% off 52w high, vol 0.65× avg

143. ✓Jul 17, 9:41 AMdecisionacted

     Agent 5 — Dip Buyer (Evolving) — pyramid

     Pyramid add-on fired at +10.27% unrealized. Added 1 sh @ $683.79 ($683.79). Position now 4 sh @ weighted avg $636.03.

144. ?Jul 16, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $678.96 < MA150 $721.99 (-6.0%), MA falling, 17.3% off 52w high, vol 0.55× avg

145. ?Jul 15, 6:02 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $664.34 < MA150 $722.15 (-8.0%), MA falling, 19.1% off 52w high, vol 0.79× avg

146. ?Jul 14, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $656.12 < MA150 $722.51 (-9.2%), MA falling, 20.1% off 52w high, vol 0.46× avg

147. ?Jul 13, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $663.22 < MA150 $722.95 (-8.3%), MA falling, 19.2% off 52w high, vol 0.88× avg

148. ?Jul 10, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $664.54 < MA150 $723.36 (-8.1%), MA falling, 19.1% off 52w high, vol 0.42× avg

149. ?Jul 9, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $668.00 < MA150 $723.87 (-7.7%), MA falling, 18.6% off 52w high, vol 0.43× avg

150. ?Jul 8, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $662.88 < MA150 $724.42 (-8.5%), MA falling, 19.3% off 52w high, vol 0.68× avg

151. ?Jul 8, 12:00 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     REGN is down ~1.93% today, a meaningful but not extreme move. No REGN-specific headline explains the move, which is common and not disqualifying. The macro context shows a flattening yield curve (T10Y2Y 2σ below trend), which typically favors defensives and pressures growth/biotech names like REGN modestly — a mild tailwind for continuation to the downside. The only headline is about VRTX, a biotech peer, suggesting possible sector-wide pressure on specialty pharma/biotech. However, with 225 minutes remaining (a full session tail), there is ample time for either continuation or mean reversion. The move is sub-2%, which is not a strong momentum signal on its own and is more prone to fading than a 3-5% impulse. No clear catalyst, no volume data to confirm conviction, and a flattish macro backdrop that provides only mild directional support. This resolves as a borderline case — slight lean toward continuation given the macro sector headwind and time available, but confidence is low. Setting at 0.50 as the floor given the system's asymmetric risk/reward design.

152. !Jul 8, 12:00 PMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     REGN is down ~1.93% today, a meaningful but not extreme move. No REGN-specific headline explains the move, which is common and not disqualifying. The macro context shows a flattening yield curve (T10Y2Y 2σ below trend), which typically favors defensives and pressures growth/biotech names like REGN modestly — a mild tailwind for continuation to the downside. The only headline is about VRTX, a biotech peer, suggesting possible sector-wide pressure on specialty pharma/biotech. However, with 225 minutes remaining (a full session tail), there is ample time for either continuation or mean reversion. The move is sub-2%, which is not a strong momentum signal on its own and is more prone to fading than a 3-5% impulse. No clear catalyst, no volume data to confirm conviction, and a flattish macro backdrop that provides only mild directional support. This resolves as a borderline case — slight lean toward continuation given the macro sector headwind and time available, but confidence is low. Setting at 0.50 as the floor given the system's asymmetric risk/reward design.

153. ?Jul 7, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $676.13 < MA150 $727.93 (-7.1%), MA falling, 17.7% off 52w high, vol 0.66× avg

154. ✓Jul 7, 3:36 PMdecisionacted

     Agent 8 — Dip Buyer (Peer-Aware) — pyramid

     Pyramid add-on fired at +10.02% unrealized. Added 1 sh @ $675.55 ($675.55). Position now 3 sh @ weighted avg $634.54.

155. ?Jul 6, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $649.97 < MA150 $725.93 (-10.5%), MA falling, 20.8% off 52w high, vol 0.48× avg

156. !Jul 2, 6:03 PMsignal

     options_momentum — insufficient_capital

157. ?Jul 2, 6:00 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $654.16 < MA150 $726.84 (-10.0%), MA falling, 20.3% off 52w high, vol 0.78× avg

158. !Jul 2, 5:45 PMsignal

     options_momentum — insufficient_capital

159. !Jul 2, 5:31 PMsignal

     options_momentum — insufficient_capital

160. !Jul 2, 5:16 PMsignal

     options_momentum — insufficient_capital

161. !Jul 2, 5:04 PMsignal

     options_momentum — insufficient_capital

162. !Jul 2, 4:46 PMsignal

     options_momentum — insufficient_capital

163. !Jul 2, 4:33 PMsignal

     options_momentum — insufficient_capital

164. !Jul 2, 4:16 PMsignal

     options_momentum — insufficient_capital

165. !Jul 2, 4:05 PMsignal

     options_momentum — insufficient_capital

166. !Jul 2, 3:46 PMsignal

     options_momentum — insufficient_capital

167. ?Jul 1, 6:05 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $624.72 < MA150 $727.56 (-14.1%), MA falling, 23.9% off 52w high, vol 0.90× avg

168. ?Jun 30, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $623.70 < MA150 $728.43 (-14.4%), MA falling, 24.0% off 52w high, vol 0.55× avg

169. ?Jun 30, 6:01 PMdecisionconsidered

     Agent 1 — Immutable — considered

     Stage 4: close $623.70 < MA150 $728.43 (-14.4%), MA falling, 24.0% off 52w high, vol 0.55× avg

170. ?Jun 30, 6:01 PMdecisionconsidered

     Agent 2 — Adaptive — considered

     Stage 4: close $623.70 < MA150 $728.43 (-14.4%), MA falling, 24.0% off 52w high, vol 0.55× avg

171. ?Jun 29, 6:01 PMdecisionconsidered

     Agent 9 — Bear Equity — considered

     Stage 4: close $631.87 < MA150 $729.19 (-13.3%), MA falling, 23.0% off 52w high, vol 0.49× avg

172. ▢Jun 25, 8:00 PMjournal

     Agent 7 — Day Trader opened long 4 @ $636.33

173. ▣Jun 25, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 4 @ $631.72 (-$18.44)

     EOD forced close — day trader never carries overnight

174. !Jun 24, 6:06 PMsignalseverity 0.15

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

175. !Jun 22, 7:21 PMsignalseverity 0.16

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

176. !Jun 22, 10:46 AMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     REGN is down 2.19% today with no clear catalyst visible in recent headlines — the news flow is entirely unrelated to REGN (AbbVie/Apogee deal, a conference announcement, and a cemdisiran FDA/EMA submission for a competitor). The absence of a specific REGN-negative catalyst suggests this could be sector rotation or sympathy selling within biotech/immunology given AbbVie's large M&A move reshuffling capital. The macro backdrop (5Y inflation expectations running 1.5σ below trend) is mildly risk-supportive and not a direct headwind for large-cap biotech. With 299 minutes remaining (nearly a full afternoon session), there is ample time for the move to continue or reverse. The 2.19% decline is meaningful and reflects real selling pressure, but without a strong directional catalyst or clear technical breakdown evidence, this is a borderline read. The AbbVie/Apogee deal could modestly weigh on REGN as a peer in the immunology space (competitive landscape narrative), providing a soft fundamental lean toward continuation. Overall, slight lean toward continuation of the downside move, but confidence is low — probability just above 0.5.

177. !Jun 18, 6:21 PMsignalseverity 0.16

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

178. !Jun 17, 6:05 PMsignalseverity 0.17

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

179. !Jun 16, 6:05 PMsignalseverity 0.16

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

180. !Jun 15, 6:05 PMsignalseverity 0.16

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

181. !Jun 11, 6:04 PMsignalseverity 0.16

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     REGN's Q1 earnings beat estimates with Dupixent and Eylea HD driving revenue growth, suggesting the underlying business remains solid. However, the stock is down 12.1% since earnings and 21.7% from its 30-day high, indicating the market is pricing in concerns beyond a single quarter — likely pipeline risks, biosimilar pressure on Eylea, or broader biotech sector rotation. The yield curve environment (T10Y3M at 1.6σ above trend) is not particularly headwind-inducing for large-cap biopharma, but the persistent post-earnings selling pressure suggests institutional skepticism that may not resolve quickly within 90 days.

182. ▢May 31, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 2 @ $636.03

183. ▢May 31, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 2 @ $636.03

184. ▢May 28, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 1 @ $634.54

185. ▢May 28, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 1 @ $634.54

186. ▢May 28, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 1 @ $634.54